AB053. P-21. M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): efficacy by BTC subtype

ABSTRACT:

Background

Biliary tract cancers (BTCs) are a group of cancers with poor prognosis and few treatment options. For 2L chemotherapy, no standard-of-care therapy exists, and overall response rates ORRs) are <10%. M7824 is an innovative first-in-class bifunctional fusion protein composed of 2 extracellular domains of transforming growth factor (TGF)-βRII (a TGF-β “trap”) fused to a human IgG1 mAb against PD-L1. We report the safety and efficacy of M7824 in Asian patients with pretreated BTC.

Methods

Patients with BTC [including intrahepatic (IHCC) and extrahepatic (EHCC) cholangiocarcinomas, gallbladder carcinoma (GC), and ampullary carcinoma (AC)] who progressed after ≥1 line of chemotherapy received M7824 1,200 mg q2w until disease progression, unacceptable toxicity, or tri

SUBMITTER: Yoo C 

PROVIDER: S-EPMC6421177 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature